Center-Authored Papers

Filters: Author is Albain, Kathy S  [Clear All Filters]
Journal Article
Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR.  2009.  Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(1):87-92. Abstract
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB et al..  2012.  Combination anastrozole and fulvestrant in metastatic breast cancer.. The New England journal of medicine. 367(5):435-44. Abstract
Moinpour CM, Donaldson GW, Liepa AM, Melemed AS, O'Shaughnessy J, Albain KS.  2012.  Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monothe. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 21(5):765-775. Abstract
Moinpour CM, Donaldson GW, Liepa AM, Melemed AS, O'Shaughnessy J, Albain KS.  2012.  Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monothe. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 21(5):765-75. Abstract
Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF et al..  2016.  Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.. British journal of clinical pharmacology. Abstract
Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS et al..  2015.  Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.. The New England journal of medicine. 372(10):923-32. Abstract
Crew KD, Albain KS, Hershman DL, Unger JM, Lo SS.  2017.  How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ breast cancer. 3:20. Abstract
Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin WJ, Martino S, Albain KS.  2008.  Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(8):1223-30. Abstract
Demichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY et al..  2015.  The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Moore HCF, Unger JM, Albain KS.  2015.  Ovarian protection during adjuvant chemotherapy.. The New England journal of medicine. 372(23):2269-70.
Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, Crowley JJ.  2013.  Patient income level and cancer clinical trial participation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(5):536-42. Abstract
Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL.  2016.  Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study.. JAMA oncology. 2(1):137-9.
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES et al..  2010.  Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(31):4747-54. Abstract
Goodwin WJ, Green SJ, Moinpour CM, Bearden JD, Giguere JK, Jiang CS, Lippman SM, Martino S, Albain KS.  2008.  Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(10):1650-6. Abstract
Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DHM, Crowley J, Gandara DR.  2008.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(15):2450-6. Abstract
Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M.  2010.  Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer.. Clinical breast cancer. 10(6):421-39. Abstract
Albain KS, Unger JM, Crowley J, Coltman CA, Hershman DL.  2009.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.. Journal of the National Cancer Institute. 101(14):984-92. Abstract
Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L et al..  2013.  Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(20):2627-33. Abstract
Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE et al..  2016.  Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.. NPJ breast cancer. 2:16024. Abstract
Zirpoli GR, Brennan PM, Hong C-C, McCann SE, Ciupak G, Davis W, Unger JM, Thomas Budd G, Hershman DL, Moore HCF et al..  2013.  Supplement use during an intergroup clinical trial for breast cancer (S0221).. Breast cancer research and treatment. 137(3):903-13. Abstract
Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, Bevilacqua JLB, de Azambuja E, El Saghir NS, Kaur R et al..  2013.  Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.. Breast (Edinburgh, Scotland). 22(5):606-15. Abstract
Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS et al..  2015.  SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(1):58-64. Abstract